The impact of pharmacological interventions varies: β-blockers such as propranolol have been shown to reduce late-stage AMD risk by 30%, likely through improved choroidal perfusion and suppression of interleukin-6 (IL-6). This evidence concerns the gene IL6 and age-related macular degeneration.